[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haploidentical-hematopoietic-stem-cell-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haploidentical-hematopoietic-stem-cell-transplant":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100648325","phase-2-to-study-lower-dose-of-cyclophosphamide-after-stem-cell-transplant-for-blood-cancers-100648325",false,"NCT07719946","To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers","Phase II Trial of Reduced Dose Post Transplant Cyclophosphamide After Haploidentical Hematopoietic Stem Cell Transplant in Hematological Malignancies","Inclusion Criteria: -\n\n* Patients age ≥ 18 years\n* ECOG performance score of 0 or 1\n\nExclusion Criteria: -\n\n* Presence of an active uncontrolled infection defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs, or radiographic findings attributable to infection.\n* Any medical or psychiatric illness which precludes the participant from giving informed consent.\n* Organ function criteria: Serious organ dysfunctions:\n* Serious cardiac dysfunction: Left ventricular ejection fraction \\\u003C 45%; no uncontrolled arrhythmias or symptomatic cardiac disease.\n* Serious pulmonary organ dysfunction: Symptomatic pulmonary disease; forced expiratory volume in one second (FEV1), forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO) =\\\u003C 50% of predicted (corrected for haemoglobin).\n* Serious renal dysfunction: Measured serum creatinine clearance =\\\u003C 60 mL\u002Fmin.\n* Serious Hepatic dysfunction: Total serum bilirubin more than twice upper normal limit or Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 3-fold higher than laboratory upper normal limits.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Cyclophosphamide is the name of a medicine given to prevent graft-versus-host-disease (GVHD) after half-matched transplant. This medicine is given on the 3rd and 4th day after stem cell transplant. The standard dose of this medicine is 50 mg per kg of the patient's weight given on the 3rd and the 4th day. However, using this medicine at this dose of 50 mg \u002F kg for 2 days is associated with certain problems such as susceptibility to infections and delay in the recovery of the immune system after stem cell transplant. Therefore, several research groups across the world have tried to reduce the dose of cyclophosphamide that is used. These groups have tried reducing the dose from 50 mg per kg to 25-40 mg per kg. These studies have shown that the reduced dose cyclophosphamide is equally effective in preventing GVHD. However, these studies are carried out on small numbers of patients and further studies are essential to confirm whether reduced dose of cyclophosphamide is equally effective. In this study, we will use cyclophosphamide at a lower dose (25 mg\u002Fkg x 2 days) and see if the lower dose results in equal efficacy but lesser toxicities This is a single-arm study. All participants will receive the same treatment; there is no comparison group.\n\nParticipants will:\n\nAdults (age ≥18) undergoing haploidentical stem cell transplant for blood cancers Receive low-dose cyclophosphamide (25 mg\u002Fkg\u002Fday) on Day 3 and Day 4 after transplant Also receive standard GVHD preventive medicines (calcineurin inhibitor and mycophenolate) Undergo regular blood tests, immune system monitoring, and GVHD assessments Have immune cell and cytokine profiles analyzed through blood samples",[26,27],"Haploidentical Hematopoietic Stem Cell Transplant","Hematological Malignancies",[29],"Low dose cyclosphosphamide","RECRUITING","2026-07-17",{"date":33,"type":34},"2026-07-22","ACTUAL",{"date":36,"type":34},"2025-03-26",{"date":38,"type":20},"2028-11-12",{"name":40,"class":41},"Tata Memorial Centre","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100612320","phase-1-ruxolitinib-enhanced-haplo-hct-for-children-and-young-adults-with-sickle-cell-disease-100612320","NCT07252050","Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease","Ruxolitinib-Enhanced Conditioning for Pediatric and Young Adult Patients With Symptomatic Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation","RUX-HAPLO","Inclusion Criteria:\n\n1. Participants with any genotypic form of SCD aged 12 - 45 years at enrollment with ≥1 of the following:\n\n   1. History of stroke and\u002For vasculopathy, including evidence of asymptomatic cerebrovascular disease for pediatric patients.\n   2. Recurrent moderate-severe acute chest syndrome (ACS)\n   3. Recurrent vaso-occlusive pain episodes requiring parenteral analgesia despite the institution of supportive care.\n   4. Need for chronic transfusion therapy to prevent vaso-occlusive complications (i.e. pain, stroke, and ACS).\n   5. For adult patients, an echocardiographic finding of tricuspid valve regurgitant jet velocity (TRJV) ≥ 2.7 m\u002Fsec.\n2. Participants must have an HLA haploidentical first degree relative (parent, sibling, or half sibling) who is willing and able to donate bone marrow.\n3. Participants must meet institutional eligibility criteria for HCT.\n\nExclusion Criteria:\n\n1. Presence of an HLA-matched sibling who is willing and able to donate bone marrow.\n2. Uncontrolled infection, evidence of active TB, Hepatitis B or C infection, or HIV seropositivity or infection.\n3. Previous HCT or solid organ transplant.\n4. CNS revascularization procedure, myocardial infarction, pulmonary embolus or deep vein thrombosis in the past 6 months.\n5. Use of medications which significantly interfere with ruxolitinib metabolism.\n6. Known hypersensitivity or severe reaction to ruxolitinib or any component of the conditioning regimen or its excipients.\n7. Inability to swallow and retain oral medication (use of nasogastric or gastrostomy tube permitted).\n8. History of malignancy except resected basal cell carcinoma or treated carcinoma in-situ.\n9. Participation in another clinical trial involving an investigational or off-label use of a drug or device in the past 3 months.\n10. Currently pregnant or breast feeding.\n11. Clinically significant, uncontrolled autoimmune disease.\n12. High-titer anti-donor specific HLA antibodies (without review and approval by Study Chair).\n13. Participant (or guardian) inability or unwillingness to comply with the dose schedule and study evaluations, comprehend or sign informed consent and utilize a highly effective method of contraception (for participants of child-bearing potential).\n14. Any condition that would, in the investigator's judgment, interfere with full participation in the study, pose a significant risk to the subject, or interfere with interpretation of study data.","12 Years","45 Years",{"count":53,"type":20},24,[55,23],"PHASE1","This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD).\n\nThis study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.",[58,59,26,60,61],"Sickle Cell Disease","Hematopoetic Stem Cell Transplant","Haploidentical Stem Cell Transplantation","Graft Failure",[63,64,65,66,67,68],"Sickle cell disease","Hematopoietic cell transplant","Ruxolitinib","Pediatric","Young Adult","Haplo","2026-06-02",{"date":71,"type":34},"2026-06-04",{"date":73,"type":20},"2026-06-08",{"date":75,"type":20},"2029-11-19",{"name":77,"class":41},"Arkansas Children's Hospital Research Institute",4]